The global Cell and Gene Therapy Manufacturing Market is experiencing explosive growth as the expanding clinical pipeline, increasing commercial approvals, and rising investment in manufacturing capacity drive demand for advanced therapy production solutions. The market is projected to grow at a CAGR of over 16% between 2026 and 2036. This comprehensive analysis explores the evolving landscape of cell therapy, gene therapy, and combination therapy manufacturing across oncology, cardiovascular, neurology, and genetic disorders applications. As the number of cell and gene therapies (CGTs) receiving regulatory approval continues to rise, industry leaders are innovating with automated manufacturing systems, closed-process platforms, and real-time digital monitoring. This article examines the primary drivers, challenges, and competitive dynamics shaping the Cell and Gene Therapy Manufacturing Market, offering valuable insights for stakeholders in this rapidly evolving biopharmaceutical sector.
Market Dynamics
Expanding Clinical Pipeline and Commercial Approvals
The Global Cell and Gene Therapy Manufacturing Market is driven by an expanding pipeline of cell and gene therapies and increasing commercial approvals. According to the Alliance for Regenerative Medicine, approximately 400 oncology-focused CGT clinical trials and around 100 programmes targeting autoimmune diseases are currently underway worldwide. As programmes progress from early-stage development to pivotal studies and commercial production, manufacturing requirements increase considerably in both scale and complexity, driving demand for GMP-grade viral vectors, plasmid DNA, cell culture media, and single-use bioprocessing technologies. The recent approval of therapies such as Fondazione Telethon ETS's Waskyra for ex vivo gene therapy highlights the accelerating commercialization of these advanced treatments.
Increasing Investment in Manufacturing Infrastructure
Growing investment in dedicated CGT manufacturing infrastructure is a key driver of market expansion. Historically, shortages of GMP-compliant viral vector production capacity, specialised cell processing facilities, and aseptic fill-finish infrastructure have limited production scalability and extended manufacturing timelines. Leading contract manufacturers are responding through strategic capacity expansion. Lonza continues to strengthen its viral vector and cell therapy manufacturing capabilities, while Thermo Fisher Scientific is expanding its global biopharmaceutical manufacturing network, including bioprocess design centres in India, Singapore, and South Korea. Public initiatives including the U.S. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and the UK Cell and Gene Therapy Catapult are also supporting infrastructure development and technology innovation.
Technological Advancements in Bioprocessing and Automation
The increasing adoption of automated manufacturing systems, closed-process platforms, and real-time digital monitoring is enabling manufacturers to enhance operational efficiency, improve product consistency, and reduce manufacturing risk across both cell therapy and viral vector production. These capabilities are especially important in autologous cell therapy manufacturing, where patient-specific production requires stringent chain-of-identity and chain-of-custody management. In April 2026, Thermo Fisher Scientific launched the Gibco CTS DynaXS, a single-use bioreactor designed to help cell therapy developers scale manufacturing more efficiently. The growing adoption of Process Analytical Technology, real-time monitoring systems, and advanced digital analytics is further enhancing process control and enabling earlier detection of manufacturing deviations.
Cell Therapy Segment Leadership
Cell therapy manufacturing holds a dominant position in the market, commanding approximately 49-52% share, driven by the volume of clinical-stage and commercial chimeric antigen receptor T cell, T-cell receptor, and stem cell-based programs. Gene therapy is the fastest-growing segment, driven by expanding adeno-associated virus and lentiviral pipelines for rare genetic, neurodegenerative, and inherited metabolic diseases. Viral vectors dominated vector type with roughly 69% share, while non-viral vectors, including lipid nanoparticles and plasmid DNA platforms, are growing fastest.
Contract Manufacturing Dominance
Contract manufacturing currently dominates the market, possessing a substantial share of roughly 60% in 2025, as biotech companies increasingly outsource production to specialized CDMOs. Biopharmaceutical companies accounted for about 61% of end-user demand, with biotechnology startups projected as the fastest-growing end-user segment as virtual biotech models and venture funding expand. The trend toward end-to-end CDMO partnerships is accelerating as sponsors seek to streamline development and reduce time to market.
Regional Outlook
North America holds the largest regional share at approximately 45-48%, supported by a dense concentration of biotech and pharmaceutical companies, an extensive CGT clinical pipeline, and a favorable regulatory environment including FDA programs such as the regenerative medicine advanced therapy designation and accelerated approval pathways. Europe represents approximately 30% of the global market, supported by favorable EMA frameworks and strong biotechnology research activity. Asia-Pacific is expected to be the fastest-growing region, at a projected CAGR of over 23%, driven by expanding biomanufacturing capacity, cost-efficient production, and government initiatives supporting advanced therapies in China, Japan, and South Korea.
Competitive Landscape
The competitive landscape features key players including Lonza, Thermo Fisher Scientific, Catalent, Charles River Laboratories, WuXi Advanced Therapies, Samsung Biologics, Novartis, and Roche. Recent developments include Lonza's expansion of US CGT manufacturing capacity in February 2025 to support late-stage and commercial CGT programs, Catalent's viral vector manufacturing upgrades in January 2025 aimed at supporting high-volume gene therapy programs, and Samsung Biologics' opening of a new 2,000-liter cell therapy manufacturing line at its Korea campus. Companies are investing in automation, closed-system manufacturing, and strategic partnerships to capture market share.
Conclusion
The Cell and Gene Therapy Manufacturing Market is poised for explosive growth driven by clinical pipeline expansion, manufacturing infrastructure investment, and technological advancement. The projected 16-17% CAGR through 2036 reflects the market's significant expansion potential. Manufacturers that successfully combine innovation with scalability and regulatory compliance will capture substantial opportunities in this dynamic biopharmaceutical sector.
Read Our Related Reports
FAQs
1. What is the projected size of the Cell and Gene Therapy Manufacturing Market by 2035?
The market is projected to grow from USD 13.7 billion in 2026 to over USD 60-80 billion by 2036, at a CAGR of approximately 16-17%.
2. What are the key therapy types in this market?
Key therapy types include Cell Therapy (immune cell therapy, stem cell therapy), Gene Therapy (viral vector, non-viral vector), and Combination Therapy, with Cell Therapy currently holding the largest share.
3. Which region leads the Cell and Gene Therapy Manufacturing Market?
North America holds the largest share at approximately 45-48%, while Asia-Pacific is the fastest-growing region at a CAGR exceeding 23%.